634 related articles for article (PubMed ID: 28670716)
1. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
[TBL] [Abstract][Full Text] [Related]
2. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
[TBL] [Abstract][Full Text] [Related]
3. Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma.
Kintz H; Nylen E; Barber A
Cell Immunol; 2020 May; 351():104069. PubMed ID: 32106933
[TBL] [Abstract][Full Text] [Related]
4. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
5. Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.
Zheng Y; Yu K; Du J; Jiang L; Zhang S; Han Y; Yu P; Tan Y
J Exp Clin Cancer Res; 2010 Sep; 29(1):121. PubMed ID: 20815894
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy of malignant solid tumors by targeting erbB2 receptors and by activating T cells.
Hu WX; Chen HP; Yu K; Shen LX; Wang CY; Su SZ; Sui WJ; Shan DM; Li HZ
Cancer Biother Radiopharm; 2012 Dec; 27(10):711-8. PubMed ID: 22988969
[TBL] [Abstract][Full Text] [Related]
7. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
VanSeggelen H; Hammill JA; Dvorkin-Gheva A; Tantalo DG; Kwiecien JM; Denisova GF; Rabinovich B; Wan Y; Bramson JL
Mol Ther; 2015 Oct; 23(10):1600-10. PubMed ID: 26122933
[TBL] [Abstract][Full Text] [Related]
8. Tumor ablation by gene-modified T cells in the absence of autoimmunity.
Wang LX; Westwood JA; Moeller M; Duong CP; Wei WZ; Malaterre J; Trapani JA; Neeson P; Smyth MJ; Kershaw MH; Darcy PK
Cancer Res; 2010 Dec; 70(23):9591-8. PubMed ID: 21098715
[TBL] [Abstract][Full Text] [Related]
9. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
11. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
12. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
Zhang T; Lemoi BA; Sentman CL
Blood; 2005 Sep; 106(5):1544-51. PubMed ID: 15890688
[TBL] [Abstract][Full Text] [Related]
13. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
Prosser ME; Brown CE; Shami AF; Forman SJ; Jensen MC
Mol Immunol; 2012 Jul; 51(3-4):263-72. PubMed ID: 22503210
[TBL] [Abstract][Full Text] [Related]
14. A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy.
Alvarez-Fernández C; Escribà -Garcia L; Vidal S; Sierra J; Briones J
J Transl Med; 2016 Jul; 14(1):214. PubMed ID: 27435312
[TBL] [Abstract][Full Text] [Related]
15. Transient stimulation expands superior antitumor T cells for adoptive therapy.
Kagoya Y; Nakatsugawa M; Ochi T; Cen Y; Guo T; Anczurowski M; Saso K; Butler MO; Hirano N
JCI Insight; 2017 Jan; 2(2):e89580. PubMed ID: 28138559
[TBL] [Abstract][Full Text] [Related]
16. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
Gargett T; Brown MP
Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
[TBL] [Abstract][Full Text] [Related]
17. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells.
Sangsuwannukul T; Supimon K; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
Int Immunopharmacol; 2020 Dec; 89(Pt B):107069. PubMed ID: 33242709
[TBL] [Abstract][Full Text] [Related]
19. A novel bispecific chimeric PD1-DAP10/NKG2D receptor augments NK92-cell therapy efficacy for human gastric cancer SGC-7901 cell.
Li M; Zhi L; Yin M; Guo C; Zhang H; Lu C; Zhu W
Biochem Biophys Res Commun; 2020 Mar; 523(3):745-752. PubMed ID: 31952789
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of chimeric FcepsilonRI gene-modified human T cells for cancer immunotherapy.
Teng MW; Kershaw MH; Jackson JT; Smyth MJ; Darcy PK
Hum Gene Ther; 2006 Nov; 17(11):1134-43. PubMed ID: 17052145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]